Investigating the Env-dependent antiviral activity and Nef-mediated antagonism of SERINC5 in HIV-1 infection

研究 HIV-1 感染中 SERINC5 的 Env 依赖性抗病毒活性和 Nef 介导的拮抗作用

基本信息

  • 批准号:
    10237249
  • 负责人:
  • 金额:
    $ 1.82万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-09-01 至 2021-10-30
  • 项目状态:
    已结题

项目摘要

The HIV-1 proteome consists of required structural and essential regulatory proteins as well as accessory proteins that increase viral fitness. These accessory proteins, Vif, Vpr, Vpu, and Nef, are involved in countering host immune responses and antagonizing so-called restriction factors, thereby increasing viral infectivity, the ability of a virion to infect and replicate in target cells. Nef, or negative factor, has a variety of activities, most of which involve modulation of signal transduction or membrane protein sorting. Nef increases the infectivity of viral particles (virions), with a mechanism that depends on cellular endosomal proteins as well as on sequences within the viral Envelope glycoprotein (Env). Two members of the serine incorporator (SERINC) protein family were identified recently as host proteins that inhibit viral infectivity and are antagonized by Nef. SERINC5 (SERC5) is the most active; it incorporates into virions and inhibits virion infectivity, potentially by altering the kinetics of virion-target cell fusion, the function of the Env protein. Despite the prevailing model that SERC5 incorporates into virions to inhibit Env function, it does not seem to co-immunoprecipitate with Env, suggesting the requirement of cofactors or other indirect interactions. Moreover, different Env proteins are differentially sensitive to SERC5, but the structural and molecular determinants of SERC5-sensitivity are unclear. To inhibit SERC5 antiviral activity, Nef coordinates with endosomal machinery to relocalize SERC5 from the plasma membrane to late endosomes. However, this model of SERC5-inhibition is derived solely from experiments in which exogenous SERC5 is expressed. Whether endogenous SERC5 is similarly modulated is unknown. Here studies are proposed to determine the mechanisms behind SERC5-mediated restriction of virion infectivity and Nef-mediated counteraction of this effect. Preliminary analysis of clade B Envs leads to the hypothesis that a region within the gp41 membrane proximal external region (MPER) is responsible for SERC5-sensitivity. This region and other putative determinants will be probed by site-directed mutagenesis. To determine whether a direct interaction of SERC5 with Env can explain antiviral activity, or instead whether SERC5-cofactors are responsible, a proximity-based labeling approach using APEX2, coupled with mass spectrometry-based proteomics, will be used to probe the interactions of SERC5 and Env. Lastly, the hypothesis that Nef downregulates endogenous SERC5 from the cell surface and traps it in late endosomes via clathrin-mediated endocytosis will be tested using cell fractionation by differential centrifugation and targeted proteomics to track the native, endogenous, unlabeled protein. When these experiments are completed, the field will have a better explanation of the effect of SERC5 on HIV-1 virion infectivity. This understanding might provide new approaches to restricting transmission, a pillar of the NIAID mission.
HIV-1蛋白质组由所需的结构和必需的调节蛋白以及 增加病毒适应性的辅助蛋白。这些辅助蛋白,Vif,Vpr,Vpu和Nef,参与 对抗宿主免疫应答并拮抗所谓的限制因子,从而增加病毒感染。 感染性,即病毒粒子感染靶细胞并在靶细胞中复制的能力。 Nef,即负性因子,具有多种活性,其中大部分涉及信号调节 转导或膜蛋白分选。Nef增加病毒颗粒(病毒体)的感染性, 依赖于细胞内体蛋白以及病毒包膜内序列的机制 糖蛋白(Env)。 丝氨酸蛋白酶(SERINC)家族的两个成员最近被鉴定为宿主 抑制病毒感染性并被Nef拮抗的蛋白质。SERINC 5(SERC 5)是最活跃的;它 可能通过改变病毒体-靶细胞的动力学, 融合,Env蛋白的功能。尽管流行的模型是SERC 5整合到病毒体中, 抑制Env功能,它似乎不与Env共免疫沉淀,这表明需要 辅因子或其他间接相互作用。此外,不同的Env蛋白对SERC 5的敏感性不同, 但SERC 5敏感性的结构和分子决定因素尚不清楚。抑制SERC 5抗病毒 活性,Nef与内体机制协调,将SERC 5从质膜重新定位到晚期, 核内体然而,该SERC 5抑制模型仅来源于其中外源性抑制的实验。 SERC 5被表达。内源性SERC 5是否被类似地调节是未知的。 在这里,研究提出,以确定背后的机制SERC 5介导的限制病毒粒子 感染性和Nef介导的这种作用的抵消。进化枝B Envs的初步分析导致了 假设gp 41膜近端外部区域(MPER)内的区域负责 SERC 5-灵敏度。该区域和其他推定的决定簇将通过定点诱变进行探测。到 确定SERC 5与Env的直接相互作用是否可以解释抗病毒活性,或者相反, SERC 5-辅因子是负责的,使用APEX 2的基于邻近的标记方法,与质量 基于光谱的蛋白质组学,将用于探测SERC 5和Env的相互作用。最后 Nef下调来自细胞表面的内源性SERC 5并将其捕获在晚期内体中的假说 通过网格蛋白介导的内吞作用将使用差速离心的细胞分级分离进行测试, 靶向蛋白质组学追踪天然的、内源性的、未标记的蛋白质。当这些实验 完成后,该领域将更好地解释SERC 5对HIV-1病毒粒子感染性的影响。这 理解可能提供新的方法来限制传播,这是NIAID使命的支柱。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Aaron Louis Oom其他文献

Aaron Louis Oom的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 1.82万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 1.82万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 1.82万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 1.82万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 1.82万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 1.82万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 1.82万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 1.82万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 1.82万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 1.82万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了